FDA clears Alzheimer's blood test diagnostics
FDA clearance of blood tests from Fuji Radio and Roche lowers diagnostic barriers for early-stage Alzheimer's, expanding the addressable population for targeted amyloid-beta therapies.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.